Phase II-III Trial of Adjuvant Radiotherapy Following Radical Prostatectomy With or Without Adjuvant Docetaxel
This randomized phase II/III trial studies docetaxel, antiandrogen therapy, and radiation therapy to see how well it works compared with antiandrogen therapy and radiation therapy alone in treating patients with prostate cancer that has been removed by surgery. Androgen can cause the growth of prostate cells.
The purpose of this study is to assess the benefit of docetaxel as measured by improvement in freedom from progression (phase II) and subsequently metastasis free survival (phase III) when given in combination with radiation and androgen deprivation in treatment of high risk prostate cancer post-radical prostatectomy.
Participants will not be paid for their participation.
- IRB Number: 1712375281 (NRG-GU002)
- Research Study Identifier: TX8709
- Principal Investigator: Nabil Adra, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required